Areas of Specialty:

• Amino acids

• Isoleucine

• Protein

• Rapamycin

• mTOR

Dudley Lamming, PhD

​​Dr. Dudley Lamming is an Associate Professor and Vice Chair for Biomedical Research of the Department of Medicine at the University of Wisconsin-Madison, where he is also an H.I. Romnes Faculty Fellow and Director of the UW-Madison Comprehensive Diabetes Center Mouse Phenotyping and Surgery Core. Dr. Lamming received his PhD in Experimental Pathology from Harvard University in 2008. He subsequently completed postdoctoral training at the Whitehead Institute for Biomedical Research, where he discovered that many of the deleterious effects of rapamycin, a pharmaceutical that extends lifespan by inhibiting the protein kinase mTORC1, were mediated by “off-target” inhibition of a second complex, mTORC2. Dr. Lamming is the author of over 100 peer-reviewed papers and the recipient of several prestigious awards, including the 2018 Nathan Shock New Investigator Award from the Gerontological Society of America. He is a fellow of the American Aging Association and of the Gerontological Society of America, and served as President of the American Aging Association from 2023-2024. His NIH-supported laboratory at the University of Wisconsin-Madison studies how diets with altered levels of specific dietary macronutrients can promote healthy aging and be used to prevent or treat age-associated diseases, including diabetes and Alzheimer’s disease, and also studies the human use of mTOR inhibitors like rapamycin to promote healthspan.